查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1800876

2025 年至 2033 年偏頭痛藥物市場報告（按治療類型、藥物類型、給藥途徑、配銷通路和地區分類）

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 123 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球偏頭痛藥物市場規模達44億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到65億美元，2025-2033年期間的複合年成長率（CAGR）為4.06%。全球偏頭痛藥物市場的成長主要得益於偏頭痛患者日益增多、治療流程知識的不斷拓展、降鈣素基因相關胜肽（CGRP）藥物等療法的開發、預防性治療的推廣以及新興市場不斷湧現的擴張機會。此外，由於北美偏頭痛發生率較高，該地區是偏頭痛藥物市場最大的地區。

偏頭痛藥物市場正經歷著巨大的變革，其不斷發展以滿足日益成長的有效藥物需求。此外，醫療保健可近性的提高也大大促進了偏頭痛藥物市場的成長。隨著醫療基礎設施的不斷轉型，尤其是在已開發國家，偏頭痛藥物的可近性正在不斷提高。大多數國家正在透過改善保險覆蓋範圍和報銷政策來提高偏頭痛藥物的可及性，以便患者能夠獲得更新、更有效的治療。醫療保險計劃的普及率不斷提高，尤其是在發展中市場，也推動了處方藥的需求。在醫療基礎設施快速發展的國家，偏頭痛治療的可近性正在提高，這支撐了市場的成長。

偏頭痛藥物市場趨勢：

認知度和診斷能力不斷提升

人們對偏頭痛及其極其嚴重的後果的認知日益加深，這推動了對偏頭痛藥物的需求。就其盛行率而言，患者仍未得到診斷或治療不足。每年六月，世界各地的頭痛社群都會努力普及大眾對偏頭痛的認知。其次，隨著越來越多的人意識到有效治療的必要性，治療需求也隨之增加，從而推動了市場的成長。偏頭痛研究基金會指出，超過3,900萬美國人患有偏頭痛，女性罹患偏頭痛的幾率是男性的三倍。偏頭痛日益被人們視為一個嚴重的健康問題，促使偏頭痛患者和醫生都在尋找最有前景的偏頭痛治療方法。

藥物研發的進展

藥物研發和科學的不斷進步促進了市場的成長。在製藥業，偏頭痛新療法的研發（R&D）是重中之重。這需要應用更有效、更安全、給藥方式更最佳化的藥物，例如採用新的給藥系統或劑型。此外，多項與偏頭痛治療相關的臨床試驗正在進行或計劃中，這進一步強化了人們的看法：研究界正在全力以赴地追求這種療法。每一項發現都開闢了一個新的市場利基，患者可以獲得各種替代療法，治療方法也不斷改進，從而提高了偏頭痛患者的生活水準。研究機構也在舉辦研討會和討論活動，以推動偏頭痛治療的進展。例如，美國神經病學學會（AAN）於2025年4月5日至9日在加州聖地牙哥舉行了2025年年會，探討急性偏頭痛的治療方法。

偏頭痛盛行率不斷上升

全球範圍內偏頭痛病例的不斷增加推動了對偏頭痛藥物的需求。越來越多的報告顯示，由於壓力、生活方式的改變和環境因素等因素，越來越多的人患有偏頭痛。人們對偏頭痛作為一種疾病的認知不斷提高，促使越來越多的人尋求治療，從而推動了偏頭痛藥物市場的發展。醫護人員越來越意識到有效、有針對性的治療的必要性，這促使專門用於治療偏頭痛的新藥的誕生。此外，由於偏頭痛的發病年齡跨度不同，但主要影響處於工作年齡的成年人，因此，工作日損失帶來的經濟壓力促使政府和醫療保健系統優先考慮有效的治療。根據Medscape在2024年發表的一篇文章，在美國，每年有超過3000萬人經歷一次或多次偏頭痛。確診病例的穩定成長推動了偏頭痛藥物市場對藥物創新的需求，預防性和急性治療的使用量都在增加。

偏頭痛藥物市場成長動力：

增加醫療支出

全球醫療保健支出的不斷成長，正在形成一個利好的偏頭痛藥物市場趨勢。各國政府和私營部門正將越來越多的資金投入到偏頭痛等疾病的預防和管理上，這些疾病已被證明會在短期內對醫療保健系統和社會產生影響。此外，全球醫療保健支出也呈現持續成長趨勢，主要用於治療慢性疾病。因此，這類人群更容易獲得醫療保健行業的產品和療法，從而刺激了對偏頭痛藥物的需求。這一趨勢在新興市場尤其明顯，因為這些市場的偏頭痛患者日益增多，這反過來又為製藥公司在治療偏頭痛症狀的療法和治療方案方面創造了獨特的機會。

健康數位化解決方案整合

數位健康解決方案的日益普及是推動市場持續成長的主要驅動力之一。行動應用程式、穿戴式裝置和遠距醫療平台正成為偏頭痛管理不可或缺的工具。這些數位平台為患者提供了監測不同偏頭痛誘因（例如食物、壓力水平和環境條件）的手段，並根據誘因進行個別化治療。透過持續追蹤偏頭痛發作和相關症狀，這些技術使患者能夠更好地了解自身病情，並提高治療依從性。此外，遠距醫療平台還促進了與醫療保健專業人員的遠距會診，從而增加了獲得專科服務的機會，尤其是在農村和服務不足的社區。這些技術也使患者能夠更好地控制病情，並提高生活品質和整體治療效果。隨著數位健康技術的進步，它們增強了傳統的藥物療法，使得更互聯互通、數據驅動的偏頭痛治療成為可能。這些技術作為常規護理的一部分，正在提高患者的積極性，並將繼續推動對偏頭痛藥物的需求，特別是那些可以透過這些數位工具進行調整或追蹤的藥物。

轉向預防性治療

偏頭痛的治療正從急性緩解轉向預防性治療，這對偏頭痛藥物市場的發展產生了至關重要的影響。從歷史上看，偏頭痛治療主要針對發作期間的緩解。但隨著對偏頭痛病理學認知的不斷進步，醫生們更加重視預防性治療，以減少發作的頻率和嚴重程度。這種轉變源自於人們越來越意識到復發性偏頭痛對患者的生活品質有很大影響，而預防性治療可以顯著提高長期療效。預防性偏頭痛治療中最重大的突破之一是降鈣素基因相關胜肽 (CGRP) 抑制劑的研發。這些生物製劑已被證明在降低偏頭痛發作頻率方面具有巨大潛力，可以為患有慢性偏頭痛的患者提供長期緩解。透過專門針對與偏頭痛發展有關的某些分子機制，CGRP 抑制劑開創了偏頭痛治療的新時代，提供了一種有針對性的機制，與現有療法相比，可提高療效並減少副作用。

偏頭痛藥物市場細分：

依治療類型分類：

  • 失敗的治療
  • 預防性治療

預防性治療佔大部分市場佔有率

預防性治療在偏頭痛藥物市場佔據主導地位，因為事實證明，預防性治療有助於降低偏頭痛發作的頻率和強度，從而改善患者的生活品質。根據美國國立衛生研究院 (NIH) 的報告，38% 的美國偏頭痛患者正在尋求預防性治療，但只有極少數人獲得了治療。前者凸顯了預防性治療在偏頭痛治療中尚未被滿足的必要性。由於偏頭痛持續存在，且預防是最佳治療方法，醫生和患者擴大使用預防性藥物來治療急性偏頭痛。因此，這種日益成長的趨勢要求將預防性方法作為偏頭痛管理的核心。

依毒品類型分類：

  • 曲坦類
  • 麥角生物鹼
  • 非類固醇抗發炎藥
  • 乙醯膽鹼抑制劑/神經毒素
  • 迪坦斯
  • 降鈣素基因相關胜肽單株抗體
  • 其他

曲坦類藥物佔據業界最大佔有率

根據偏頭痛藥物市場預測，曲坦類藥物佔據市場主導地位，因為偏頭痛藥物能夠快速緩解偏頭痛症狀，尤其針對頭痛、頸痛、噁心以及對光和噪音的敏感性。例如，根據美國國家神經疾病和中風研究所 (NINDS) 的報告，曲坦類藥物是美國處方率最高的藥物，也是美國醫生最常用的急性偏頭痛治療藥物。它們透過興奮血管中的交感神經纖維並阻礙疼痛訊號傳遞到大腦來發揮作用。在美國，超過 20% 的女性和 9% 的男性患有偏頭痛，因此在像曲坦類藥物這樣的有效急性治療藥物方面，住院護理仍然存在巨大的缺口。這些藥物在醫療保健提供者中的日益普及和廣泛接受證明了其在偏頭痛藥物市場中的地位，可用於治療急性發作，使患者相信其緩解疼痛的能力。

依給藥途徑分類：

  • 口服
  • 注射劑
  • 其他

Oral 代表領先的細分市場

口服給藥途徑推動了偏頭痛藥物市場的價值，因為口服藥物使用方便且易於使用，患者可以在家中或旅途中自行治療，無需醫療監督。根據美國國家神經疾病和中風研究所 (NINDS) 的數據，口服藥物是醫療保健提供者治療偏頭痛最常用的方法。與其他途徑相比，其口服製劑也能更快地起效，這有助於緩解急性偏頭痛發作中的患者的痛苦。由於 20% 的美國女性和 9% 的男性患有偏頭痛，對口服治療的需求增加。這些治療方法的可及性和有效性使口服藥物途徑在偏頭痛藥物市場中佔據主導地位。

依配銷通路分類：

  • 醫院藥房
  • 零售藥局
  • 其他

醫院藥房設在醫院內，為住院和門診患者提供藥物和藥局服務。在偏頭痛藥物市場中，醫院藥局在幫助急性偏頭痛患者就診急診或門診方面發揮著至關重要的作用。他們擁有豐富的庫存藥品，包括曲坦類藥物和其他專門用於治療偏頭痛的藥物。這確保了急性偏頭痛患者能夠快速獲得藥物並得到治療。

零售藥局是位於商業區和住宅區的藥局，向大眾提供處方藥和非處方藥。除了零售藥局外，需要急性和預防性治療的偏頭痛患者也會去這些藥局取得藥物，因為這是重要的照護端。他們為患者提供諮詢和支持，這對於正確使用藥物和嚴格遵循治療方案至關重要。由於零售藥局提供的便利，它們正在成為偏頭痛藥物分銷和供應的關鍵參與者，透過為偏頭痛患者（即使在周邊不同的社區）提供服務。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據偏頭痛藥物市場最大佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是偏頭痛藥物最大的市場。

北美由於其疾病高發生率而佔據市場主導地位，而該地區擁有強大的醫療基礎設施和高額醫療支出，這構成了市場成長的支柱。根據美國國家神經疾病和中風研究所（NINDS）的資料，每 10 個美國人中就有 1 個患有偏頭痛。除此之外，北美有幾家大型製藥公司主要從事抗偏頭痛藥物的研發，從而建立了有利於研究和產品開發的環境。此外，美國食品藥物管理局（FDA）等政府機構為確保治療偏頭痛的藥物核准速度所做的努力也促進了該地區市場的擴張。因此，這些因素使北美在全球偏頭痛藥物產業中一直處於領先地位。

（請注意，這只是關鍵參與者的部分列表，完整列表在報告中提供。）

偏頭痛藥物市場的主要參與者不斷致力於研發和商業化，以滿足偏頭痛患者的需求。安進、禮來和梯瓦製藥等製藥公司正在推廣尖端療法，例如降鈣素基因相關胜肽 (CGRP) 抑制劑和吉非替尼，用於治療急性偏頭痛和預防偏頭痛。例如，根據美國國立衛生研究院 (NIH) 的偏頭痛藥物市場研究報告，這些公司目前正在招募受試者進行試驗，旨在評估藥物的安全性和有效性。這些公司的優先事項還包括制定相應的計劃、提高人們對偏頭痛的普遍認知以及提供適當的治療。

本報告回答的關鍵問題

  • 偏頭痛藥物市場有多大
  • 偏頭痛藥物市場的未來前景如何
  • 推動偏頭痛藥物市場的關鍵因素有哪些
  • 哪個地區佔據偏頭痛藥物市佔率最大
  • 全球偏頭痛藥物市場領先的公司有哪些

本報告回答的關鍵問題

  • 偏頭痛藥物市場有多大？偏頭痛藥物市場未來前景如何？
  • 推動偏頭痛藥物市場發展的關鍵因素有哪些？
  • 哪個地區佔據偏頭痛藥物市場的最大佔有率？
  • 全球偏頭痛藥物市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球偏頭痛藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依治療類型

  • 失敗的治療
  • 預防性治療

第7章：市場區隔：依藥物類型

  • 曲坦類
  • 麥角生物鹼
  • 非類固醇抗發炎藥
  • 乙醯膽鹼抑制劑/神經毒素
  • 迪坦斯
  • 降鈣素基因相關胜肽單株抗體
  • 其他

第8章：市場區隔：依行政途徑

  • 口服
  • 注射劑
  • 其他

第9章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Allergan Plc (Abbvie Inc.)
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
Product Code: SR112025A2543

The global migraine drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets. Furthermore, North America represents the largest region due to the high prevalence of diseases in the area.

The migraine drugs market is going through enormous transformations as it continues to develop to address growing demand for effective medication. In addition, increased healthcare accessibility is greatly contributing to the growth of the migraine drugs market. As healthcare infrastructures continue to transform, especially in developed nations, availability to migraine medication is on the rise. Most nations are enhancing the availability of migraine medication through improved insurance coverage and reimbursement policies, so patients have access to newer and more effective treatments. Increased penetration of health insurance schemes, especially in developing markets, is also driving the demand for prescription drugs. In nations with rapidly developing healthcare infrastructure, access to migraine care is increasing, which is supporting the market growth.

Migraine Drugs Market Trends:

Growing Awareness and Diagnosis

The growing perception of migraine headaches and their very disabling kind of outcome is driving the demand for migraine drugs. Regarding its prevalence, the visitors remain undiagnosed or undertreated. Every year in June headache communities throughout the world work towards raining awareness about migraine among the masses. Secondly, with an increasing number of people realizing the need for effective treatments, they also increase the demand for treatments, driving the market growth. The Migraine Research Foundation states that over 39 million Americans suffer from migraines, with women being three times more prone to experiencing them than men. This growing recognition of migraines as a serious health issue encourages both migraine patients and medical practitioners to look for the most promising migraine treatment variation.

Advancements in Drug Development

Constant improvement in drug development and science is contributing to the growth of the market. In the pharma industry, research and development (R&D) of new treatments for migraine patients pose one of the significant workloads. This entails the application of drugs that are more effective, safer, and better in terms of modes of administration, such as utilization of new delivery systems or drug forms. Moreover, several clinical trials related to migraine therapy are either ongoing or planned, which only reinforces the perception that the research world is on its case in pursuit of the therapy. Each discovery is offering a new market niche where various alternatives are becoming accessible to patients, and the treatment is becoming improved, enhancing the living standard of migraineurs people. Research bodies are also conducting seminars and discussion events to make progress about migraine treatments. For instance, the American Academy of Neurology (AAN) conducted its 2025 annual meeting, held in San Diego, California from 5 April to 9 April 2025, to discuss about treatments for acute migraine.

Increasing Prevalence of Migraine Cases

The increasing number of migraine cases worldwide is driving the demand for migraine medication. Reports are continually coming in of increasing numbers of people having migraines because of factors like stress, lifestyle changes, and environmental factors. Increasing awareness about migraine as a disease condition is making more people go for treatment, thus driving the market for migraine medication. Health workers are increasingly seeing the necessity of effective, focused treatments, which is leading to the creation of new drugs specifically designed for migraine management. Also, since migraine crosses different ages but mainly impacts adults in their working age, the economic pressure of lost workdays is encouraging governments and the healthcare system to prioritize successful treatment. According to an article published by Medscape in 2024, In the United States, over 30 million individuals experience one or more migraine headaches annually. This steady rise in diagnosed cases is driving the need for pharmaceutical innovation within the migraine drugs market, with both preventive and acute treatments increasing usage.

Migraine Drugs Market Growth Drivers:

Increasing Healthcare Spending

The increasing healthcare spending globally is developing a favorable migraine drug market trend. The governments and the private approach are focusing increasingly funds on prevention and management of diseases such as migraines that are proven to short-termily impact healthcare systems and society. Additionally, global healthcare expenditure has been witnessing an ever-increasing trend of growth, mostly to address chronic conditions of disease management. Consequently, such individuals have greater access to the healthcare industry products and remedies, boosting the need for migraine medication. This trend is highest in the new markets, where migraines are becoming increasingly prevalent and this in turn creates particular opportunities for drug companies in terms of the therapies and treatments they offer for treating the symptoms of migraines.

Integration of Digital Solutions for Health

Growing incorporation of digital health solutions is one of the major drivers strengthening the market growth, which continues to grow. Mobile apps, wearables, and telemedicine platforms are becoming indispensable management tools for migraines. These digital platforms provide patients with the means to monitor different migraine triggers like food, stress levels, and environmental conditions, which are then treated on an individual basis. Through the ongoing tracking of migraine attacks and related symptoms, these technologies are allowing patients to better comprehend their condition and be more compliant with treatment. In addition, telemedicine platforms are facilitating distant consultations with healthcare professionals, which is increasing access to specialist services, especially in rural and underserved communities. These technologies are also allowing patients to take greater control of their condition, enhancing quality of life and overall therapeutic outcomes. With advances in digital health technologies, they augment the conventional drug therapies so that a more connected and data-informed care for migraines is made possible. The alignment of these technologies as a part of normal care is creating higher patient activation and will continue to drive the need for migraine drugs, especially ones that can be adjusted or tracked through these digital tools.

Shift Towards Preventive Therapies

There is a shift in the treatment of migraine away from acute relief and toward preventive therapy, which is critically impacting the development of the migraine drugs market. Historically, migraine therapies were directed largely at relief during an active attack. But as knowledge of migraine pathology has progressed, medical practitioners are placing greater emphasis on preventive therapy to decrease frequency as well as severity of attacks. This change is facilitated by increasing realization that recurrent migraines have a great effect on patients' quality of life, and preventive therapies can significantly enhance long-term effects. One of the most significant breakthroughs in preventive migraine therapies is the breakthrough for the creation of calcitonin gene-related peptide (CGRP) inhibitors. These biologics have proven enormous potential in attenuating the frequency of migraine attacks, providing long-term relief to patients suffering from chronic migraines. By specifically targeting certain molecular mechanisms implicated in migraine development, CGRP inhibitors bring with them a new era of migraine therapy, providing a targeted mechanism that provides improved efficacy and reduced side effects over existing therapies.

Migraine Drugs Market Segmentation:

Breakup by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment

Preventive treatment accounts for the majority of the market share

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others

Triptans hold the largest share of the industry

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Oral represents the leading market segment

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region's market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include:

  • Abbott Laboratories
  • Allergan Plc (Abbvie Inc.)
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies.

Key Questions Answered in This Report

  • 1.How big is the migraine drugs market?
  • 2.What is the future outlook of migraine drugs market?
  • 3.What are the key factors driving the migraine drugs market?
  • 4.Which region accounts for the largest migraine drugs market share?
  • 5.Which are the leading companies in the global migraine drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players